Damora Therapeutics Inc(DMRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -124.78 | Insider Own | 22.08% | Shs Outstand | 61.7M | Perf Week | 1.9% |
| Market Cap | 1.33B | Forward P/E | - | EPS next Y | -3.49% | Insider Trans | 0.09% | Shs Float | 48.1M | Perf Month | 6.23% |
| Enterprise Value | 0.92B | PEG | - | EPS next Q | -0.48 | Inst Own | 88.18% | Short Float | 10.71% | Perf Quarter | -24.75% |
| Income | -0.26B | P/S | - | EPS this Y | 48.78% | Inst Trans | 17.64% | Short Ratio | 9.86 | Perf Half Y | -15.26% |
| Sales | 0.00B | P/B | 3.44 | EPS next 5Y | 13.54% | ROA | -94.32% | Short Interest | 5.15M | Perf YTD | -6.61% |
| Book/sh | 6.25 | P/C | 2.45 | EPS past 3/5Y | -36.14% -34.72% | ROE | -100% | 52W High | -43.93% ($38.33) | Perf Year | 192.38% |
| Cash/sh | 8.76 | P/FCF | - | Sales past 3/5Y | - | ROIC | -50.93% | 52W Low | 334.14% ($4.95) | Perf 3Y | 60.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -850.33% | Gross Margin | - | Volatility(W/M) | 7.63% 7.49% | Perf 5Y | -73.95% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 19.73 | EPS Q/Q | 80.38% | Profit Margin | - | RSI (14) | 49.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.73 | Sales Q/Q | - | SMA20 | 5.17% ($20.43) | Beta | 1.53 | Target Price | $46.89 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/10 | SMA50 | -8.68% ($23.53) | Rel Volume | 0.65 | Prev Close | $22.01 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -16.24% ($25.66) | Avg Volume(3M) | 0.52M | Price | $21.49 |
| IPO | 2020/10/29 | Option/Short | No/Yes | Trades | 4888 | Volume | 339,421 | Change | -2.36% |
🩸 Damora Therapeutics (DMRA) is a US biotech company developing antibody therapies targeting mutant calreticulin (mutCALR). The company has a differentiated pipeline for patients with myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis, and has changed its name from Galecto to focus on treating blood disorders.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
Traded less than usual. That is 65% of its average volume.
DMRA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.8% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -74.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 88.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #138 of 597 in the industry
Based on market cap of $1B.
TSHA#135 Taysha Gene Therapies Inc $1B PER - 
OMER#136 Omeros Corp $1B PER 12.8 
NKTR#137 Nektar Therapeutics $1B PER - DMRA#138 Damora Therapeutics Inc $1B PER - 
KARD#139 Kardigan Inc $1B PER - 
FAQ
What kind of company is DMRA?
DMRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DMRA?
The market cap of DMRA is approximately $1.3B, ranking 2,376 within its sector.
What is the 52-week high and low for DMRA?
DMRA has recorded a 52-week high of $38.33 and a low of $4.95.
